Cronos Group (CRON) Stock
Key stats
- Market cap
- $1.37B
- Price / Earnings ratio
- 18.5x
- EPS (TTM)
- $0.19
- Volume
- Loading
- 52-week high
- $3.61
- 52-week low
- $2.28
- EPS vs analyst estimate
- +450.0%Q3 FY25 · $0.07 vs -$0.02
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with CRON
Recent news
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
CRON
Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know
Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know
CRON
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
CRON
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
CRONNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.94
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.03
- SMA 50
- $3.31
- Price above SMA 50
- EMA 50
- $3.28
- Price above EMA 50
- SMA 200
- $2.87
- Price above SMA 200
- EMA 200
- $2.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.02 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
CRONCronos (CRON) Upgraded to Strong Buy: Here's What You Should Know
Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know
CRONCronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
CRONAre Medical Stocks Lagging Cronos Group (CRON) This Year?
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
CRON
The Best Way Marijuana Stock Investing Can Work For You
The Best Way Marijuana Stock Investing Can Work For You
CRON
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
CRON
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
CRON
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
CRON
Cronos Group Q2 Earnings Call Highlights
Cronos Group Q2 Earnings Call Highlights
CRON
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
CRONNews tone: automated (AI) classification of the article's content, not a price prediction.
About Cronos Group
Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group’s portfolio includes PEACE NATURALS™, a global health and wellness platform, two adult-use brands, COVE™ and Spinach™, and three hemp-derived CBD brands, Lord Jones™, Happy Dance™ and PEACE+™.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Ryan Gorenstein J.D. | President, CEO & Chairman | 1987 |
| Ms. Anna Shlimak | Chief Financial Officer | 1986 |
| Ms. Shannon Buggy | Senior VP & Global Head of People | 1970 |
| Mr. Jeffrey David Jacobson | Chief Growth Officer | 1986 |
| Mr. Adam Wagner | General Manager of Cronos Israel | 1983 |
| Mr. Jared Matthew Kenost | VP, Principal Accounting Officer & Controller | — |
| Mr. Harrison Aaron | Senior Director of Investor Relations & Corporate Development | — |
| Mr. Terry Gregory-Joseph Doucet | General Counsel & Corporate Secretary | 1990 |
| Mr. Arye Weigensberg | Senior VP and Head of Research & Development | 1983 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 72.94
- MACD 12/26/9
- 0.06
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.03
- SMA 50
- $3.31
- Price above SMA 50
- EMA 50
- $3.28
- Price above EMA 50
- SMA 200
- $2.87
- Price above SMA 200
- EMA 200
- $2.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- -
- Average
- -
- High
- -
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -32.5 | -6.9 | ||||||||||
| 2022 | -12.1 | -6.5 | +12.8 | -22.6 | -3.8 | -1.4 | +10.1 | -4.1 | -4.7 | +13.0 | -3.7 | -22.1 |
| 2023 | +0.8 | -13.5 | -8.5 | -4.1 | -6.9 | +13.2 | -4.9 | +7.3 | +1.5 | -7.7 | +16.1 | -0.5 |
| 2024 | -5.2 | -3.7 | +29.2 | +11.4 | -4.4 | -7.5 | +6.5 | -3.8 | -2.2 | -1.9 | -3.7 | -2.4 |
| 2025 | -7.8 | +10.8 | -8.1 | +5.0 | +5.9 | -0.5 | +3.1 | +33.3 | +11.2 | -5.6 | -2.8 | +5.6 |
| 2026 | -7.0 | +6.4 | -4.6 | +6.4 | +7.6 | -1.4 | -1.0 | +19.1 | -2.4 | +2.8 | +11.7 |
